Title |
Donepezil for mild cognitive impairment
|
---|---|
Published in |
Cochrane database of systematic reviews, July 2006
|
DOI | 10.1002/14651858.cd006104 |
Pubmed ID | |
Authors |
Jacqueline Birks, Leon Flicker |
Abstract |
Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or diagnostic criteria for MCI, and MCI remains a vague term and those so described are a heterogeneous population, consisting of people who may rapidly progress to dementia but also of people with stable cognitive deficits and some who may actually improve. Treatment in the very earliest stages of AD may delay progression to AD. Donepezil (Aricept, E2020), a cholinesterase inhibitor, has been shown to benefit all severities of AD including mild and it would be reasonable to investigate its efficacy for those with MCI. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
India | 1 | <1% |
Sweden | 1 | <1% |
Germany | 1 | <1% |
Unknown | 222 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 31 | 14% |
Student > Master | 29 | 13% |
Student > Bachelor | 25 | 11% |
Student > Ph. D. Student | 19 | 8% |
Student > Doctoral Student | 14 | 6% |
Other | 53 | 23% |
Unknown | 55 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 54 | 24% |
Psychology | 23 | 10% |
Neuroscience | 14 | 6% |
Agricultural and Biological Sciences | 13 | 6% |
Nursing and Health Professions | 11 | 5% |
Other | 42 | 19% |
Unknown | 69 | 31% |